Overview Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome Status: Terminated Trial end date: 2021-04-13 Target enrollment: Participant gender: Summary A Phase 1b study to determine the effect of oral olorinab on gastrointestinal transit in adult participants with irritable bowel syndrome (IBS). Phase: Phase 1 Details Lead Sponsor: Arena Pharmaceuticals